WEST HAVEN, Conn., Jan. 23, 2015 /PRNewswire/ --NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
No direct adverse clinical effects were found upon administration of the FluCide candidate intravenously at doses of up to 300mg/kg/day for 14 days (a total of 4,200mg/kg) in rats. Organs were examined for gross histological observations. Microscopic histological tissue analysis was also performed. There were no adverse histological findings in gross organ level histological examination, nor were there any adverse findings in microscopic histological analysis. Equally importantly, there were no meaningful effects observed on animal weight gain, food consumption, hematology, or clinical chemistry at the end of the 14 day dosing period.
The study was conducted at BASi (Bioanalytical Systems, Inc., NASDAQ: BASI) in Evansville, Indiana. The study was performed in a cGLP-like fashion, compliant with BASi Evansville standard operating procedures. BASi has over 40 years of experience providing contract research services and niche instrumentation to the life sciences, primarily drug research and development.
These results are in agreement with the previously reported results of a non-GLP toxicology study in mice. The current study results also support the Company's positive findings in animal models of infection with different influenza A virus strains in which no safety or toxicology concerns were observed. The Company has previously reported that many of its FluCide candidates demonstrated extremely high anti-influenza activity in those models.
This study was developed in collaboration with BASi and conducted by BASi in a cGLP-like fashion in order to understand the safety parameters of FluCide intravenous dosing.
The next phase of the toxicology package studies will involve larger animals, and will require much larger quantities of the drug candidate. The Company is in the process of commissioning operations at the new 1 Controls Drive, Shelton, CT facility in order to perform the scale up studies needed for making the large quantities of materials in a controlled manner. These upcoming studies will be performed in cGLP compliant manner to provide safety and toxicology data that are required for an IND submission to regulatory agencies.
About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
SOURCE NanoViricides, Inc.
Read the rest here:
NanoViricides Reports that the FluCide Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study ...
- Advances in nanotechnology's fight against cancer - December 27th, 2013 [December 27th, 2013]
- Nanotechnology and Medicine - Nanomedicine and Disease ... - December 27th, 2013 [December 27th, 2013]
- Nanomedicine: Nanotechnology, Biology and Medicine - Official Site - December 27th, 2013 [December 27th, 2013]
- Nanomedicine Fact Sheet - December 27th, 2013 [December 27th, 2013]
- Nanomedicine, bionanotechnology | NanomedicineCenter.com - December 27th, 2013 [December 27th, 2013]
- Nanomedicine - Wikipedia, the free encyclopedia - December 27th, 2013 [December 27th, 2013]
- Nanomedicine for drug delivery - Srinivas Sridhar - Video - December 28th, 2013 [December 28th, 2013]
- IT-CRS 2013 workshop- Prof. Kevin Breackmans. Studying nanomedicine biobarriers - Video - December 30th, 2013 [December 30th, 2013]
- Nanotechnology in Medicine - UnderstandingNano - January 3rd, 2014 [January 3rd, 2014]
- Nanomedicine - Nanorobots in Medicine - UnderstandingNano - January 8th, 2014 [January 8th, 2014]
- Nanomedicine: Challenges and opportunities - Video - January 13th, 2014 [January 13th, 2014]
- Global Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019: Transparency Market Research - January 16th, 2014 [January 16th, 2014]
- NANOMEDICINE 1 - Video - January 17th, 2014 [January 17th, 2014]
- Researchers measure minuscule particles with 'tiny diving boards' - January 20th, 2014 [January 20th, 2014]
- High Unmet Needs in Therapeutics to Spur Growth in the Market for Nanotechnology in Drug Delivery, According to New ... - January 21st, 2014 [January 21st, 2014]
- Nanomedicine Market - Video - January 22nd, 2014 [January 22nd, 2014]
- Nanomedicine and human upper limit - Video - January 23rd, 2014 [January 23rd, 2014]
- Animated Nanomedicine movie - Video - February 2nd, 2014 [February 2nd, 2014]
- In Vitro Innovation: Testing Nanomedicine With Blood Cells On A Microchip - February 4th, 2014 [February 4th, 2014]
- Nanomedicine Market is Expected to Reach USD 177.60 Billion in 2019 - February 7th, 2014 [February 7th, 2014]
- NANOMEDICINE 4: AYDEN JACOB FROM UCSF - Video - February 7th, 2014 [February 7th, 2014]
- New Live-Cell Printing Technology Works Like Ancient Chinese Woodblocking - February 10th, 2014 [February 10th, 2014]
- NANOMEDICINE HANGOUT: ARSALAN SHABBIR MD - Video - February 14th, 2014 [February 14th, 2014]
- Using Mathematical Models to Understand Nanoscale Roughness Published by Dove Medical Press - February 17th, 2014 [February 17th, 2014]
- NTU and Northwestern University to set up $70 million nanomedicine research institute - February 20th, 2014 [February 20th, 2014]
- Interview with Medical Animator YURIY SVIDINENKO, about Nanotechnology Videos - Video - February 21st, 2014 [February 21st, 2014]
- TTU MSE nanomedicine lab NML 2013 f - Video - February 21st, 2014 [February 21st, 2014]
- Nanomedicine Vietsubtitles - Video - February 24th, 2014 [February 24th, 2014]
- Biochips for Better Cancer Therapy in NanoMedicine - Video - February 27th, 2014 [February 27th, 2014]
- 13 Nanomedicine Part 1 - Video - February 28th, 2014 [February 28th, 2014]
- 13 Nanomedicine part 2 - Video - February 28th, 2014 [February 28th, 2014]
- practicum nanomedicine pws Nicole en jordy - Video - March 6th, 2014 [March 6th, 2014]
- Nanomedicine, Detto tra Noi, 4 marzo 2014 - Video - March 6th, 2014 [March 6th, 2014]
- Brown Symposium XXXVI - Mauro Ferrari: "Nanomedicine and New Societal Horizons" - Video - March 9th, 2014 [March 9th, 2014]
- nanomedicine nanobiotix itele - Video - March 9th, 2014 [March 9th, 2014]
- NANOMEDICINE HANGOUT UNIVERSITY OF MIAMI ARSALAN SHABBIR MD - Video - March 16th, 2014 [March 16th, 2014]
- NANOMEDICINE HANGOUT1 - Video - March 21st, 2014 [March 21st, 2014]
- NANOMEDICINE HANGOUT - Video - March 21st, 2014 [March 21st, 2014]
- Ideas @Davos | Sonia Trigueros | Breakthroughs in Nanomedicine - Video - March 22nd, 2014 [March 22nd, 2014]
- Nanomedicine: towards development of patient-friendly drug-delivery systems - Video - March 23rd, 2014 [March 23rd, 2014]
- Nanomedicine Research - March 26th, 2014 [March 26th, 2014]
- Mining Genome Information for New Starting Points in Personalized Cancer Nanomedicine - Video - March 28th, 2014 [March 28th, 2014]
- Cancer Stem Cells as Preferential Target for Personalized Cancer Nanomedicine - Video - March 28th, 2014 [March 28th, 2014]
- Nanomedicine Against Malaria: Use of Poly-based Nanovectors for the Drug Delivery to Plasmodium - Video - March 29th, 2014 [March 29th, 2014]
- Panel - The Horizon of Nanomedicine and Targeted Drug Delivery - Video - March 29th, 2014 [March 29th, 2014]
- Panel - The Regulation Environment in Nanomedicine -- The Step to the Last Phase of Translation - Video - March 29th, 2014 [March 29th, 2014]
- Looking and Listening to Light from Liposome Nanostructures for Cancer Theranostics - Video - March 29th, 2014 [March 29th, 2014]
- Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of ... - April 2nd, 2014 [April 2nd, 2014]
- Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED - Video - April 4th, 2014 [April 4th, 2014]
- How IBM Is Using Nanotechnology To Tackle MRSA And HIV - April 5th, 2014 [April 5th, 2014]
- In latest generation of tiny biosensors, size isn't everything - April 14th, 2014 [April 14th, 2014]
- Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global ... - April 17th, 2014 [April 17th, 2014]
- doctors-hospital-surgery-AFprelax-210414.jpg - April 21st, 2014 [April 21st, 2014]
- Nanomedicine - Video - April 25th, 2014 [April 25th, 2014]
- Nanomedicine Presentation - Video - May 6th, 2014 [May 6th, 2014]
- Nanomedicine Promo - Video - May 6th, 2014 [May 6th, 2014]
- A skinful of nanoparticles starts to show - May 16th, 2014 [May 16th, 2014]
- nanomedicine edit1 - Video - May 17th, 2014 [May 17th, 2014]
- UB spinoff Nanobiotix working to bring cancer treatment to market - May 29th, 2014 [May 29th, 2014]
- DGAP-News: MagForce AG: MagForce AG to present at dbAccess German, Swiss & Austrian Conference 2014, held by Deutsche ... - June 2nd, 2014 [June 2nd, 2014]
- New nanomedicine by NTU and SERI scientists to bring relief to glaucoma patients - June 4th, 2014 [June 4th, 2014]
- New glaucoma treatment replaces the hassle of applying eyedrops daily - June 4th, 2014 [June 4th, 2014]
- Cancer Nanomedicine - The Cancer Nanomedicine Blog - June 5th, 2014 [June 5th, 2014]
- No More Eye Drops for Glaucoma - June 10th, 2014 [June 10th, 2014]
- Nanomatriaux 2014 - AGuIX in nanomedicine - Video - June 19th, 2014 [June 19th, 2014]
- Introduction to nanomedicine with emphasis on carrier-mediated drug targeting - Video - June 20th, 2014 [June 20th, 2014]
- Challenging the Old Order to Set New Frontiers in Nanoscience & Nanotechnology - June 21st, 2014 [June 21st, 2014]
- Welcome - Summer School on Nanomedicine and Innovation - Video - June 24th, 2014 [June 24th, 2014]
- Nanomedicine and IP - Video - June 25th, 2014 [June 25th, 2014]
- Global Nanomedicine Market: Industry Analysis, Size, Share,Growth, Trends, and Forecast 2013 - 2019 - June 30th, 2014 [June 30th, 2014]
- Scientists engineer nanoparticles to prevent bone cancer, strengthen bones - July 2nd, 2014 [July 2nd, 2014]
- Global Nanomedicine Market Projected to be Worth USD 177.60 billion by 2019 - July 4th, 2014 [July 4th, 2014]
- Nanobiotix revenue for the 2nd quarter of 2014 - July 11th, 2014 [July 11th, 2014]
- magforce - Using advanced nanomedicine for innovative therapies - Video - July 25th, 2014 [July 25th, 2014]
- Shelton firms products in the pipeline could end diseases - July 29th, 2014 [July 29th, 2014]
- In the Quest to Treat Intracerebral Hemorrhage, Nanomaterials Show Promise - July 31st, 2014 [July 31st, 2014]
- Researchers to track effects of revolutionary new medicines - August 8th, 2014 [August 8th, 2014]
- Nanomedicine & RA with Dr. Bottini - Video - August 8th, 2014 [August 8th, 2014]
- Cellular Surgeons: The New Era of Nanomedicine - Full Program - Video - August 8th, 2014 [August 8th, 2014]
- DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of ... - August 9th, 2014 [August 9th, 2014]